The Trump administration has replaced Centers for Disease Control and Prevention (CDC) Director Susan Monarez with Jim O’Neill, currently serving as Deputy Secretary of Health and Human Services (HHS). The change was announced just one day after Monarez’s abrupt dismissal, which she is contesting.
The White House confirmed her removal following an HHS statement earlier in the week, despite criticism from health experts and lawmakers. The leadership shake-up has already caused turbulence inside the CDC. Within 24 hours of Monarez’s firing, four senior officials submitted their resignations, raising concerns about the agency’s ability to maintain stability.
Jim O’Neill’s Background
O’Neill is a Silicon Valley investor and a familiar figure in Republican political circles. He previously served as CEO of the Thiel Foundation, funded by billionaire venture capitalist Peter Thiel, a well-known Trump ally and donor.
O’Neill is not new to government service. During the George W. Bush administration, he held a senior role at HHS as principal associate deputy secretary, working on health policy issues. More recently, he was sworn in as Deputy Secretary of HHS in June 2025, becoming a top deputy to Secretary Robert F. Kennedy Jr.
His appointment comes at a pivotal moment for the CDC, which has faced criticism for its pandemic-era responses and ongoing debates over the balance between politics and science in public health decisions.
White House Signals More Changes Ahead
Although O’Neill will serve as acting director, the White House suggested a permanent replacement could be named soon. Press secretary Karoline Leavitt said on Thursday that Secretary Kennedy would announce a formal successor to Monarez “very soon.”
Until then, O’Neill will take charge of the CDC during a time of uncertainty, tasked with steering the agency despite internal turmoil and external political scrutiny.
Reaction From Public Health Leaders and Lawmakers
Monarez’s firing and the subsequent resignations have alarmed public health groups, who fear the agency is being destabilized at a time when steady leadership is crucial. Critics argue that repeated leadership changes undermine morale and weaken the CDC’s ability to respond effectively to emerging health crises.
In Congress, the move has drawn bipartisan attention. Senators Bill Cassidy (R-La.) and Bernie Sanders (I-Vt.), who chair the Senate Committee on Health, Education, Labor and Pensions, announced plans to conduct oversight hearings to examine the situation. Their involvement signals that the issue could evolve into a wider political battle over the independence and credibility of federal health agencies.
O’Neill’s Past Views Raise Questions
Beyond his connections in politics and business, O’Neill’s past statements have resurfaced as a point of contention. In a 2014 speech, he suggested that the Food and Drug Administration (FDA) should focus solely on ensuring the safety of new drugs, rather than evaluating both safety and effectiveness.
He argued that once safety was demonstrated, patients should be allowed to decide whether to use the drug, regardless of its proven effectiveness. This stance clashes with the FDA’s current mission, which requires proof that treatments are both safe and effective before they reach the market.
Public health experts have voiced concern that such an approach could leave patients vulnerable to ineffective or unproven treatments, raising questions about how O’Neill might influence health policy in his new role.
Growing Debate Over Politics in Public Health
The CDC has long been regarded as a cornerstone of science-based policymaking, but its leadership has increasingly been caught in political crossfire. The removal of Monarez and the installation of O’Neill—a figure with strong political and business ties—has reignited fears that the administration is prioritizing loyalty and ideology over scientific expertise.
Health organizations caution that repeated disruptions at the top could erode public trust. The CDC already faces challenges in restoring confidence following contentious debates over pandemic response measures. Lawmakers and watchdog groups worry that further politicization could damage its credibility even more.
While some Republicans have defended the president’s authority to make leadership changes, others have joined Democrats in urging transparency and oversight. The split highlights growing unease across the political spectrum about the balance between politics and science in shaping public health policy.
